SkinBioTherapeutics
Macclesfield
About SkinBioTherapeutics
The SkinBioTherapeutics platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair, and reduce bacterial load.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $7.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2024)
- Ticker: lse:SBTX
- Website: skinbiotherapeutics.com
- Phone: +01614682760
Industries & Categories
Biopharma
Social Profiles
Canonical: https://fsome.com/organization/skinbiotherapeutics-177767 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.